SCHEMBL14328043

SCHEMBL14328043

NCc1ccc(CSc2ccccc2Br)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.48
MAOA P21397 1/20 0.47
MAOB P27338 1/20 0.47
HTR7 P34969 1/20 0.43
LOXL2 Q9Y4K0 4/20 0.41
TAAR1 Q96RJ0 2/20 0.41
LMNA P02545 1/20 0.38
HRH3 Q9Y5N1 1/20 0.37
SLC6A4 P31645 1/20 0.37
CA1 P00915 3/20 0.36
CA2 P00918 3/20 0.36
CA9 Q16790 3/20 0.36
CA4 P22748 2/20 0.36
CA7 P43166 2/20 0.36
CA12 O43570 2/20 0.36
CA14 Q9ULX7 2/20 0.36
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4334230 0.84 POLB (0.61) POLBMAOAMAOBHTR7LMNA
SCHEMBL31011604 0.77 APP (0.49) MAOAMAOBHTR7LMNACA1
SCHEMBL15916334 0.75 DAO (0.46) POLBMAOAMAOBHTR7LMNA
SCHEMBL1118636 0.73 POLB (0.52) POLBSLC6A4CA1CA2CA9
SCHEMBL30484939 0.73 POLB (0.52) POLBSLC6A4CA1CA2CA9
SCHEMBL1118653 0.73 POLB (0.52) POLBMAOAMAOBHTR7LMNA
SCHEMBL30231962 0.73 POLB (0.52) POLBMAOAMAOBHTR7LMNA
SCHEMBL19675345 0.72 POLB (0.71) POLBMAOBLMNAKDM4EMEN1
SCHEMBL16242598 0.71 POLB (0.87) POLBSLC6A4MEN1ALDH1A1MAPT
SCHEMBL21315691 0.71 POLB (0.64) POLBLOXL2LMNASLC6A4CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150353538-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) 2015-12-10 US disclosed
US-20120329786-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF MYREXIS, INC. (US) 2012-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353538-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF NFATC1, CD47, CD4 POLB 4109/4885MAOA 2903/4885MAOB 2199/4885
US-20120329786-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF NFATC1, CD47, CD4 POLB 4109/4885MAOA 2903/4885MAOB 2199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.